Current data is sufficient to recommend a current standard of care

類似資料

• Single institution best recommendation is HIPEC with cisplatin and docetaxel
  著者:: Sugarbaker, Paul H., 等
  出版事項: (2021)
• PIPAC may work but more data is needed
  著者:: Sugarbaker, Paul H., 等
  出版事項: (2021)
• The options are neoadjuvant, adjuvant, or no chemotherapy at all: further data is needed
  著者:: Sugarbaker, Paul H., 等
  出版事項: (2021)
• Genetic targets for cancer control are a reality
  著者:: Sugarbaker, Paul H., 等
  出版事項: (2021)
• A model for accurate histopathologic assessment refines treatment options
  著者:: Sugarbaker, Paul H., 等
  出版事項: (2021)